Overexpression of EGFR in high-risk or metastatic cutaneous squamous cell carcinoma (cSCC) is associated with poor prognosis, and emerging evidence suggests that EGFR inhibitors may offer potential benefit for patients with advanced disease [14,15,16]. Here, EGFR is linked to skin squamous cell carcinoma.